Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,827,168 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,827,168 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,825,740 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,825,740 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,849,737 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,849,737 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,859,453 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,859,453 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,842,366 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,842,366 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,596 | $155.10 | $1,178,134.28 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 606,681 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $154.58 to $155.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,222 | $153.98 | $650,121.71 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 614,277 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.58 to $154.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,503 | $153.19 | $230,243.67 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 618,499 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.58 to $153.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 798 | $152.16 | $121,424.72 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 620,002 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.57 to $152.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 492 | $157.02 | $77,253.05 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,753,776 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.73 to $157.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,066 | $155.92 | $166,208.06 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,754,268 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.69 to $156.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 50,011 | $155.10 | $7,756,551.07 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,755,334 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $154.58 to $155.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 28,374 | $153.98 | $4,369,144.85 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,805,345 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.58 to $154.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,468 | $153.19 | $1,603,564.66 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,833,719 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.58 to $153.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,333 | $152.17 | $811,517.28 |
DisclosureSEC source: 0001576280-21-000012 · wf-form4_161239879900811.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,844,187 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.57 to $152.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 21:49 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCOMMON STOCK | 279,127 | $129.54 | $36,158,111.58 |
DisclosureSEC source: 0001576280-21-000004 · wf-form4_161005614488813.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,849,520 Read SEC document |
| January 01, 2021 Filed Jan 6, 2021 01:42 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 565,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-21-000001 · wf-form4_160989735123472.xml · derivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,130,382 Underlying: COMMON STOCK · 565,192 shares Expires 2027-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: One-third of the granted performance-based restricted stock units vested and converted into shares of common stock based on the Issuer's achievement of the stock price milestone, as certified by the Issuer's compensation committee on January 2, 2021. Read SEC document |
| January 01, 2021 Filed Jan 6, 2021 01:42 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 565,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-21-000001 · wf-form4_160989735123472.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,128,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2020 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,505,280 Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 23,923 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001576280-20-000006 · wf-form4_160876020666584.xml · derivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,582 Underlying: COMMON STOCK · 23,923 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 23,923 | $4.18 | $99,998.14 |
DisclosureSEC source: 0001576280-20-000006 · wf-form4_160876020666584.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,563,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2020 Filed Feb 5, 2021 22:03 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 92,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-21-000013 · wf-form4_161256258436886.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,530,280 Read SEC document |
| October 27, 2020 Filed Oct 27, 2020 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,400 | $110.03 | $374,111.86 |
DisclosureSEC source: 0001628280-20-014895 · wf-form4_160383646927255.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 620,800 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $110.00 to $110.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 27, 2020 Filed Oct 27, 2020 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,000 | $109.28 | $1,092,834.00 |
DisclosureSEC source: 0001628280-20-014895 · wf-form4_160383646927255.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 624,200 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $109.00 to $109.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 27, 2020 Filed Oct 27, 2020 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 13,272 | $108.19 | $1,435,937.50 |
DisclosureSEC source: 0001628280-20-014895 · wf-form4_160383646927255.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 634,200 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $108.00 to $108.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 27, 2020 Filed Oct 27, 2020 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9,678 | $107.44 | $1,039,819.80 |
DisclosureSEC source: 0001628280-20-014895 · wf-form4_160383646927255.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 647,472 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $107.00 to $107.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 27, 2020 Filed Oct 27, 2020 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 25,263 | $106.35 | $2,686,800.89 |
DisclosureSEC source: 0001628280-20-014895 · wf-form4_160383646927255.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 657,150 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $106.00 to $106.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 27, 2020 Filed Oct 27, 2020 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 14,238 | $105.35 | $1,500,037.37 |
DisclosureSEC source: 0001628280-20-014895 · wf-form4_160383646927255.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 682,413 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $105.00 to $105.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 26, 2020 Filed Oct 27, 2020 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,613 | $105.02 | $484,472.48 |
DisclosureSEC source: 0001628280-20-014895 · wf-form4_160383646927255.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 696,651 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $105.00 to $105.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 13,136 | $105.15 | $1,381,314.77 |
DisclosureSEC source: 0001628280-20-014895 · wf-form4_160383646927255.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 701,264 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $105.00 to $105.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,801 | $103.45 | $186,313.63 |
DisclosureSEC source: 0001628280-20-014610 · wf-form4_160322520341129.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 714,400 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $103.2825 to $103.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 11,000 | $102.89 | $1,131,783.40 |
DisclosureSEC source: 0001628280-20-014610 · wf-form4_160322520341129.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 716,201 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $102.28 to $103.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,599 | $101.81 | $1,079,035.43 |
DisclosureSEC source: 0001628280-20-014610 · wf-form4_160322520341129.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz Investments, L.P. Disclosed balance after: 727,201 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $101.28 to $102.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 21:01 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 30,880 | $111.09 | $3,430,585.81 |
DisclosureSEC source: 0001628280-20-013978 · wf-form4_160141327473559.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,539,532 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $111.00 to $111.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 21:01 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 44,120 | $110.44 | $4,872,789.28 |
DisclosureSEC source: 0001628280-20-013978 · wf-form4_160141327473559.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,570,412 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $110.00 to $110.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,733 | $95.82 | $166,055.71 |
DisclosureSEC source: 0001628280-20-013342 · wf-form4_159925444154752.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,614,532 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $95.80 to $95.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 28,267 | $95.30 | $2,693,980.78 |
DisclosureSEC source: 0001628280-20-013342 · wf-form4_159925444154752.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,616,265 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $94.80 to $95.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 16,967 | $94.10 | $1,596,548.89 |
DisclosureSEC source: 0001628280-20-013342 · wf-form4_159925444154752.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,644,532 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $93.70 to $94.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 19,477 | $93.23 | $1,815,809.55 |
DisclosureSEC source: 0001628280-20-013342 · wf-form4_159925444154752.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,661,499 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $92.70 to $93.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 8,556 | $92.17 | $788,566.31 |
DisclosureSEC source: 0001628280-20-013342 · wf-form4_159925444154752.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,680,976 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $91.70 to $92.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:55 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 15,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-011826 · wf-form4_159666092811461.xml · derivative · entry 11 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,505 Underlying: COMMON STOCK · 15,000 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:55 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,010 | $85.98 | $86,842.53 |
DisclosureSEC source: 0001628280-20-011826 · wf-form4_159666092811461.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,689,532 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $85.35 to $86.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:55 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,800 | $84.51 | $321,148.26 |
DisclosureSEC source: 0001628280-20-011826 · wf-form4_159666092811461.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,690,542 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $84.34 to $85.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:55 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,190 | $83.89 | $854,885.97 |
DisclosureSEC source: 0001628280-20-011826 · wf-form4_159666092811461.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,694,342 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $83.34 to $84.315, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:55 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 15,000 | $4.18 | $62,700.00 |
DisclosureSEC source: 0001628280-20-011826 · wf-form4_159666092811461.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,704,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:55 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 60,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-011826 · wf-form4_159666092811461.xml · derivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,505 Underlying: COMMON STOCK · 60,000 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:55 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 11,939 | $86.76 | $1,035,784.66 |
DisclosureSEC source: 0001628280-20-011826 · wf-form4_159666092811461.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,689,532 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $86.57 to $87.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:55 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 43,164 | $86.24 | $3,722,415.88 |
DisclosureSEC source: 0001628280-20-011826 · wf-form4_159666092811461.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,701,471 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $85.57 to $86.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:55 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,897 | $85.27 | $417,567.68 |
DisclosureSEC source: 0001628280-20-011826 · wf-form4_159666092811461.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,744,635 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $84.57 to $85.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:55 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 60,000 | $4.18 | $250,800.00 |
DisclosureSEC source: 0001628280-20-011826 · wf-form4_159666092811461.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,749,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 20,108 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-010229 · wf-form4_159408074472014.xml · derivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 690,505 Underlying: COMMON STOCK · 20,108 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,108 | $84.40 | $431,115.20 |
DisclosureSEC source: 0001628280-20-010229 · wf-form4_159408074472014.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,689,532 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 15,000 | $83.99 | $1,259,886.00 |
DisclosureSEC source: 0001628280-20-010229 · wf-form4_159408074472014.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,694,640 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $83.40 to $84.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 20,108 | $4.18 | $84,051.44 |
DisclosureSEC source: 0001628280-20-010229 · wf-form4_159408074472014.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,709,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 54,892 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-010229 · wf-form4_159408074472014.xml · derivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,613 Underlying: COMMON STOCK · 54,892 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.